Suven Life Sciences' (NSE:SUVEN, BOM:530239) global phase 3 study for Masupirdine in agitation associated with Alzheimer's dementia achieved 76% patient enrollment.
The 375-patient study is being conducted across Europe and North America, according to a Tuesday filing on Indian bourses.
Patient enrollment is expected to be complete by September 2026, with data readout targeted for April 2027.